Ethiopia gets 108,000 doses of COVID-19 vaccine from AVAT

As part of the first monthly shipment of Johnson & Johnson vaccinations, the African Vaccination Acquisition Trust (AVAT) announced the arrival in Ethiopia of 108,000 vaccine doses.

AVAT is delighted to announce that, 108,000 vaccination doses of Johnson & Johnson single-shot vaccines will be shipped to Ethiopia. This is part of a total shipment of 6.4 million vaccine doses to African Union member countries in August 2021. Members who bought vaccinations through AVAT will continue to receive shipments for the foreseeable future. UNICEF provides logistics and delivery services to Member States in conjunction with the Africa Medical Supplies Platform (AMSP).

These shipments are part of a historic COVID-19 vaccine advance procurement deal signed by AVAT on March 28, 2021 for the purchase of 220 million doses of the Johnson & Johnson single-shot COVID-19 vaccine, with the option to acquire an additional 180 million doses. The agreement and the beginning of delivery represent the first time that African Union Member States have jointly acquired vaccinations to protect the African population’s health. The 400 million vaccinations obtained by AVAT are enough to immunize one-third of Africa’s population.

The deal with Johnson & Johnson was made possible by a USD 2 billion facility granted by the African Export-Import Bank (Afreximbank), which also serves as the Financial and Transaction Advisers, Guarantors, Instalment Payment Advisers, and Payment Agents. The United Nations Economic Commission for Africa (UNECA) provided technical support with the financial arrangements and the AU Ministers of Finance’s alignment.

The Federal Democratic Republic of Ethiopia’s Minister of Health, Lia Tadesse, hailed the delivery of the vaccinations, saying, “The acquisition of these vaccines would strengthen our national COVID-19 immunization program- in addition to helping the current COVID rollout.”

The African COVID-19 Vaccine Acquisition Task Team was established in November 2020 under the African Union chairmanship of HE President Cyril Ramaphosa, President of the Republic of South Africa, as part of the African Union’s COVID-19 Vaccine Development and Access Strategy, with the goal of vaccinating at least 60% of the African population with safe and effective vaccines.

This vaccine purchase and deployment is also backed by an innovative collaboration between the World Bank and the African Union, African Vaccine Acquisition Task Team, which aims to increase access to vaccinations across the continent.

AU, J&J Sign Deal for 400 Million Doses of Covid-19 Vaccines

Johnson & Johnson, an American pharmaceutical company, has announced that it will begin supplying the African Union (AU) with 400 million doses of its single-shot Covid-19 vaccine in the third quarter.

According to a related announcement, all African Union member states will have access to 220 million doses of the Johnson & Johnson single-shot Covid-19 vaccine through the African Vaccine Acquisition Trust (AVAT), which was formed in November 2020.

According to a joint statement released by the African Union, the African Vaccine Acquisition Task Team (AVATT), the African Export-Import Bank (Afreximbank), the Africa Centres for Disease Control and Prevention (Africa CDC), and the Africa Medical Supplies Platform (AMSP), an extra 180 million doses may be requested.

Africa CDC Director, Dr. John Nkengasong, said: “The Africa CDC proposed to the African Union that a minimum of 750 million Africans (60 percent) be immunized if Covid-19 is to be contained. This exchange helps Africa to reach approximately half of the goal. The main feature of this vaccine is that it is a single-dose vaccine, making it easy to roll out rapidly and safely, saving lives.”

President of South Africa, AU Champion for the Covid-19 vaccine plan and purchase, and Chairman of AVATT, Cyril Ramaphosa, accepted the landmark deal, which he initiated jointly with the corporation during his term as AU Chairperson.

“This agreement is a big step toward ensuring the health of all Africans. It is also a strong example of African unity and what we can do by collaboration between the public, private, and foreign sectors that prioritize citizens,” Ramaphosa said.

The vast majority of supplies will be manufactured at Aspen Pharma’s massive pharmaceutical processing facility in South Africa.

Afreximbank President Benedict Oramah stated, “We are extremely honored to have been offered the chance by the African Union to promote this significant transaction under the auspices of the Africa Vaccine Acquisition Task(AVATT) Team in the middle of a very tight Covid-19 vaccine market.”

“We look forward to beginning the implementation of the US$2 billion Vaccine Procurement facility approved by the Bank’s Board of Directors to assist the continent in beginning to rid itself of the pandemic and restore its economy as Financial and Transaction Consultants, Guarantors, Installment Payment Facility Arrangers, and Payment Officers.”

Oramah stated that the money would help intra-African trade and that “we have already begun engagement with our financial partners” to obtain additional funding to support procurement if Africa agrees to purchase the additional 180 million doses.

AU countries were invited to place pre-orders for the vaccines prior to the signing of the deal, and “many countries expressed strong preference for this particular vaccine. The majority of countries have already finished their pre-orders,” reads the statement.